Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473446 | 1.00 | TSHR (0.42) | TSHRMAOAMAOBCA1CA2 | |
| SCHEMBL4503274 | 0.84 | TSHR (0.43) | TSHRMAOAMAOBCA1CA2 | |
| SCHEMBL59871 | 0.79 | — | — | |
| SCHEMBL29471383 | 0.79 | — | — | |
| Ammonia Solution, Strong SCHEMBL23320033 | 0.76 | MAOA (0.40) | TSHRMAOAMAOBCA1CA2 | |
| SCHEMBL16439994 | 0.76 | — | — | |
| SCHEMBL16519521 | 0.76 | MEN1 (0.46) | TSHRCA1CA2CYP1A2NPC1 | |
| SCHEMBL4860727 | 0.74 | ABCG2 (0.50) | TSHRMAOAMAOBNPC1RAB9A | |
| SCHEMBL730025 | 0.74 | — | — | |
| SCHEMBL8710 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-10-01 | — | — | US | disclosed |
| WO-2017004026-A1 | ANTI-CD 123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-2714685-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2875026-B1 | IMIDAZOPYRIDINE DERIVATIVE USED IN THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-09-21 | — | — | EP | disclosed |
| EP-2729150-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1755684-B1 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| EP-3053913-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160215096-A1 | PREPARATION OF IMIDE OLIGOMERS VIA CONCURRENT REACTIVE EXTRUSION | POLYONE CORPORATION (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2720697-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-4014906-A | Process for the manufacture of anthraquinone compounds | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | TSHR 1910/4885MAOA 609/4885MAOB 160/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | TSHR 4603/4885MAOA 155/4885MAOB 259/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | TSHR 705/4885MAOA 700/4885MAOB 944/4885 |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | TSHR 4030/4885MAOA 3640/4885MAOB 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.